Economic evaluation of the effects of using the eH-ETB (P1vital® eHealth-Emotional Test Battery) to guide the antidepressant treatment of depressed patients
Dates: 2015-2019
Funding: EC H2020 (No 696802)
Collaborator(s): P1Vital, UK; https://predictproject.p1vitalproducts.com/meet-the-team/
Website: https://predictproject.p1vitalproducts.com/
Information: Judit Simon (Cost Effectiveness and Clinical Utility Team co-PI); Susanne Mayer, Nataša Perić
It commonly takes weeks before clinicians are able to identify effective antidepressant (AD) treatment for depressed patients. During this period a patients’ ability to work and function socially is severely impaired by their illness. The P1vital® PReDicT Test is a medical device that is able to identify, early in treatment, whether an AD is working and thus significantly reduce the time required to initiate effective treatment and thereby accelerate remission. The objective of this multi-centre, within-trial cost-utility analysis was to compare societal costs (health and social care resource use, patient costs, informal care, lost productivity) and outcomes (health-related quality of life, social functioning, capability well-being) of the PReDicT Test with standard of care in six European countries (Germany, France, Spain, UK, The Netherlands).
Result(s):
- Browning M, Bilderbeck A, Dias R, Dourish CT, Kingslake J, Deckert J, et al. The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. Neuropsychopharmacol. 2021 Jun;46(7):1307-1314. DOI: 10.1038/s41386-021-00981-z
- Simon J, Perić N, Mayer S, Deckert J, Gorwood P, Pérez V, et al. on behalf of the PReDicT group. Cost-effectiveness of the predict test: results and lessons learned from a european multinational depression trial. EPP0934. Eur Psychiatry. 2020 Jul;63(S1):S45-S282. DOI: 10.1192/j.eurpsy.2020.5
- Simon J, Harmer CJ, Kingslake J, Dawson GR, Colin T D, Goodwin GM: Value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: A modelling study, BMJ Evidence Based Mental Health. doi:10.1136/ebmental-2019-300109
- Simon J, Perić N, Mayer S, Deckert J, Gorwood P, Pérez V, Reif A., Ruhe H, Veltman D, Morriss R, Bilderbeck A, Dawson G, Dourish C, Dias R, Kingslake J, Browning M, on behalf of the PReDicT group (2019). PMH21 Cost-effectiveness of the Predict Test: Results and Lessons learned from a European Multinational Depression Trial Value in Health, 22, S684. DOI: 10.1016/j.jval.2019.09.1495
- Dawson, GR, Guo, B, Kingslake, J, Ruhe, HG, Veltman, D, Deckert, J, Reif, A., Gorwood, P, Perez, V, Simon, J, Harmer, CJ, Goodwin, GM, Dias, R, Dourish, CT, Bilderbeck, AC, Pearce, L, Campbell, S, Morriss, R, Browning, M (2019): Results of the predict randomised controlled trial: clinical effects of using the predict test to guide antidepressant treatment in depression. European Neuropsychopharmacology, 29(Suppl 6):S53-S54, DOI: 10.1016/j.euroneuro.2019.09.112
- Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. (2017) The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study Protocol for a Randomised Controlled Trial. Trials. 18(1):558. DOI: 10.1186/s13063-017-2247-2